Australia is closely watching the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist , representing a significant advance in weight loss . Early clinical trials have demonstrated impressive https://mile-high-peptides029516.bloghins.com/91063/emerging-medication-in-australia-a-potential-breakthrough-for-reducing-body-weight